Sevel Tablet

Sevel 400 mg Tablet সম্পর্কে

বাংলাদেশে Sevel 400 mg Tablet ট্যাবলেট হিসেবে পাওয়া যায়; এতে Sevelamer Hydrochloride আছে (৪০০ mg)। Sevel-এর সাথে Sevelamer Hydrochloride-এর অন্য ব্র্যান্ডের দাম নিচে তুলনা করে দেখুন। Sevel প্রস্তুত করেছে The ACME Laboratories Ltd। তালিকাভুক্ত প্রতি ইউনিটের দাম ৪৫.১৩ টাকা। ডাক্তারের প্রেসক্রিপশন মেনে চলুন এবং অন্য ব্র্যান্ড খাওয়া যাবে কি না তা ফার্মাসিস্টের কাছ থেকে জেনে নিন।

Sevel 400 mg Tablet কী?

Sevel 400 mg is a tablet product of The ACME Laboratories Ltd. that contains Sevelamer Hydrochloride. Sevelamer Hydrochloride is a new treatment for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. Elevated serum phosphorus levels or uncontrolled hyperphosphatemia leads to development of secondary hyperparathyroidism, renal bone disease, calcification of vascular and nonvascular tissues, and cardiovascular disease. Whether it suits you is a decision for your doctor.

Sevel-এর ব্যবহার

Sevelamer Hydrochloride is indicated for the reduction of serum phosphorus in patients with end-stage renal disease (ESRD). Ask your doctor whether it is right for your condition.

Sevel কীভাবে ব্যবহার করবেন

Sevel is taken by mouth. Swallow the tablet with water. You can take it with or without food. If you miss a dose, ask your doctor or pharmacist what to do. Complete the course exactly as prescribed.

Sevel-এর পার্শ্বপ্রতিক্রিয়া

Sevelamer may cause dyspepsia, peritonitis, diarrhea, nausea, constipation, pruritus, abdominal distension, vomiting, fatigue, anorexia, arthralgia and less commonly ileus, bowel obstruction and bowel perforation. Tell your doctor if any side effect bothers you or does not go away. Contact your doctor if you notice anything unusual after taking it.

সতর্কতা ও নিরাপত্তা

The safety and efficacy of Sevelamer in patients with dysphagia, swallowing disorders, severe GI motility disorders including severe constipation, or major GI tract surgery have not been established. Sevelamer is contraindicated in patients with hypophosphatemia or bowel obstruction and in patients with known hypersensitivity to Sevelamer Hydrochloride or any of its constituents. Sevelamer should be used during breastfeeding only if the potential benefit justifies the potential risks. Keep out of reach of children.

সাধারণ প্রশ্ন

Why is Sevel prescribed?

Sevelamer Hydrochloride is indicated for the reduction of serum phosphorus in patients with end-stage renal disease (ESRD). Ask your doctor whether it is right for your condition.

How should I take Sevel?

Sevel is taken by mouth. Swallow the tablet with water.

What are the side effects of Sevel?

Sevelamer may cause dyspepsia, peritonitis, diarrhea, nausea, constipation, pruritus, abdominal distension, vomiting, fatigue, anorexia, arthralgia and less commonly ileus, bowel obstruction and bowel perforation. Tell your doctor if any side effect bothers you or does not go away.

Who should be careful with Sevel?

The safety and efficacy of Sevelamer in patients with dysphagia, swallowing disorders, severe GI motility disorders including severe constipation, or major GI tract surgery have not been established. Sevelamer is contraindicated in patients with hypophosphatemia or bowel obstruction and in patients with known hypersensitivity to Sevelamer Hydrochloride or any of its constituents.

Tablet
জেনেরিক নাম
Sevelamer Hydrochloride
শক্তি
400 mg
ডোজ ফর্ম
Tablet
প্রস্তুতকারক
The ACME Laboratories Ltd.
বাংলাদেশে দাম

৳ ৪৪.২৩ ৳ ৪৫.১৩ ২% ছাড় প্রতি ইউনিট

দাম হালনাগাদ: ১৬ Nov ২০২৬

আরও পাওয়া যায়

800 mg (Tablet)

নির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Sevelamer Hydrochloride is indicated for the reduction of serum phosphorus in patients with end-stage renal disease (ESRD).

ফার্মাকোলজি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Sevelamer Hydrochloride is a new treatment for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. Elevated serum phosphorus levels or uncontrolled hyperphosphatemia leads to development of secondary hyperparathyroidism, renal bone disease, calcification of vascular and nonvascular tissues, and cardiovascular disease. It is a calcium-free and aluminium-free nonabsorbed polymer phosphate binder, it does not cause calcium and aluminium toxicity. When taken with meals it inhibits intestinal absorption of ingested phosphate.

মাত্রা ও সেবনবিধি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Patients not taking a Phosphate Binder: The recommended starting dose of Sevelamer is 800 to 1600 mg, which can be administered as two to four 400 mg Sevelamer tablets, with meals based on serum phosphorus level. Renophos 400 Recommendation for the patients with hyperphosphatemia is given below-

Starting dose of Renophos for dialysis patients not taking any phosphate binder:
  • Serum Phosphorus >5.5 and <7.5 mg/dL: 800 mg (2 tablets) three times daily with meals
  • Serum Phosphorus ≥7.5 and <9.0 mg/dL: 1200 mg (3 tablets) three times daily with meals
  • Serum Phosphorus ≥9.0 mg/dL: 1600 mg (4 tablets) three times daily with meals
Starting dose for dialysis patients switching from calcium acetate to Sevelamer:
  • Calcium Acetate 667 mg (1 tablet): Sevelamer 800 mg (2 tablets)
  • Calcium Acetate 1334 mg (2 tablets): Sevelamer 1200 mg (3 tablets)
  • Calcium Acetate 2001 mg (3 tablets): Sevelamer 2000 mg (5 tablets)
Dose titration guideline:
  • Serum Phosphorus >5.5 mg/dL: Increase 400 mg (1 tablet) per meal at 2 week intervals
  • Serum Phosphorus 3.5-5.5 mg/dL: Maintain current dose
  • Serum Phosphorus <3.5 mg/dL: Decrease 400 mg (1 tablet) per meal
Dose titration for all patients taking Sevelamer: Dosage should be adjusted based on the serum phosphorus concentration with a goal of lowering serum phosphorus to 5.5 mg/dl or less. The dose may be increased or decreased by one tablet per meal at two week intervals as necessary.

ঔষধের মিথষ্ক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Sevelamer has been studied in human drug-drug interaction studies with ciprofloxacin, digoxin, warfarin, enalapril, metoprolol and iron.

প্রতিনির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Sevelamer is contraindicated in patients with hypophosphatemia or bowel obstruction and in patients with known hypersensitivity to Sevelamer hydrochloride or any of its constituents.

পার্শ্ব প্রতিক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Sevelamer may cause dyspepsia, peritonitis, diarrhea, nausea, constipation, pruritus, abdominal distension, vomiting, fatigue, anorexia, arthralgia and less commonly ileus, bowel obstruction and bowel perforation.

গর্ভাবস্থায় ও স্তন্যদানকালে

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Pregnancy Category C. No adequate and controlled studies have been conducted using Sevelamer in nursing mothers. Sevelamer should be used during breastfeeding only if the potential benefit justifies the potential risks.

সতর্কতা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

The safety and efficacy of Sevelamer in patients with dysphagia, swallowing disorders, severe GI motility disorders including severe constipation, or major GI tract surgery have not been established. Caution should be exercised when Sevelamer is used in patients with these GI disorders.

মাত্রাধিক্যতা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Over dosages of Sevelamer in patients was never reported. Since Sevelamer is not absorbed, the risk of systemic toxicity is low.

ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।